AXTI vs. ARWR

Last updated Apr 1, 2026

Compare and contrast key facts about AXT, Inc. (AXTI) and Arrowhead Pharmaceuticals, Inc. (ARWR).

Performance

AXTI vs. ARWR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in AXT, Inc. (AXTI) and Arrowhead Pharmaceuticals, Inc. (ARWR). The values are adjusted to include any dividend payments, if applicable.

AXTI vs. ARWR - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
AXTI AXT, Inc.	248.50%	653.46%	-9.58%	-45.21%	-50.28%	-7.94%	120.00%	-0.00%	-50.00%	81.25%
ARWR Arrowhead Pharmaceuticals, Inc.	-5.56%	253.14%	-38.56%	-24.56%	-38.82%	-13.59%	20.97%	410.71%	237.50%	137.42%

Fundamentals

Market Cap AXTI : $2.55B ARWR : $8.82B
EPS AXTI : -$0.48 ARWR : $1.46
PS Ratio AXTI : 28.41 ARWR : 7.96
PB Ratio AXTI : 9.45 ARWR : 15.52
Total Revenue (TTM) AXTI : $88.33M ARWR : $1.09B
Gross Profit (TTM) AXTI : $11.24M ARWR : $1.08B
EBITDA (TTM) AXTI : -$14.38M ARWR : $360.26M

Returns By Period

In the year-to-date period, AXTI achieves a 248.50% return, which is significantly higher than ARWR's -5.56% return. Over the past 10 years, AXTI has outperformed ARWR with an annualized return of 36.43%, while ARWR has yielded a comparatively lower 29.03% annualized return.

AXTI

• 1D: 8.06%
• 1M: 50.34%
• YTD: 248.50%
• 6M: 1,169.04%
• 1Y: 3,941.13%
• 3Y*: 142.82%
• 5Y*: 35.86%
• 10Y*: 36.43%

ARWR

• 1D: 8.76%
• 1M: -0.90%
• YTD: -5.56%
• 6M: 81.79%
• 1Y: 392.15%
• 3Y*: 35.15%
• 5Y*: -1.34%
• 10Y*: 29.03%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

AXTI vs. ARWR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AXTI

AXTI Risk / Return Rank: 100
AXTI Sharpe Ratio Rank: 100
AXTI Sortino Ratio Rank: 99
AXTI Omega Ratio Rank: 99
AXTI Calmar Ratio Rank: 100
AXTI Martin Ratio Rank: 100

ARWR

ARWR Risk / Return Rank: 99
ARWR Sharpe Ratio Rank: 99
ARWR Sortino Ratio Rank: 98
ARWR Omega Ratio Rank: 97
ARWR Calmar Ratio Rank: 99
ARWR Martin Ratio Rank: 99

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AXTI vs. ARWR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for AXT, Inc. (AXTI) and Arrowhead Pharmaceuticals, Inc. (ARWR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	AXTI	ARWR	Difference
Sharpe ratio Return per unit of total volatility	32.68	5.59	+27.08
Sortino ratio Return per unit of downside risk	6.95	4.63	+2.33
Omega ratio Gain probability vs. loss probability	1.86	1.60	+0.26
Calmar ratio Return relative to maximum drawdown	102.50	14.35	+88.15
Martin ratio Return relative to average drawdown	305.89	39.33	+266.56
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

AXTI vs. ARWR - Sharpe Ratio Comparison

The current AXTI Sharpe Ratio is 32.68, which is higher than the ARWR Sharpe Ratio of 5.59. The chart below compares the historical Sharpe Ratios of AXTI and ARWR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	AXTI	ARWR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	32.68	5.59	+27.08
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.40	-0.02	+0.42
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.46	0.39	+0.07
Sharpe Ratio (All Time) Calculated using the full available price history	0.08	-0.01	+0.09

Correlation

The correlation between AXTI and ARWR is 0.15, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

AXTI vs. ARWR - Dividend Comparison

Neither AXTI nor ARWR has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

AXTI vs. ARWR - Drawdown Comparison

The maximum AXTI drawdown since its inception was -98.57%, roughly equal to the maximum ARWR drawdown of -99.24%. Use the drawdown chart below to compare losses from any high point for AXTI and ARWR.

Drawdown Indicators

	AXTI	ARWR	Difference
Max Drawdown Largest peak-to-trough decline	-98.57%	-99.24%	+0.67%
Max Drawdown (1Y) Largest decline over 1 year	-36.59%	-24.64%	-11.95%
Max Drawdown (5Y) Largest decline over 5 years	-90.65%	-88.94%	-1.71%
Max Drawdown (10Y) Largest decline over 10 years	-92.45%	-88.96%	-3.49%
Current Drawdown Current decline from peak	-16.74%	-61.42%	+44.68%
Average Drawdown Average peak-to-trough decline	-82.78%	-81.40%	-1.38%
Ulcer Index Depth and duration of drawdowns from previous peaks	12.26%	8.99%	+3.27%

Volatility

AXTI vs. ARWR - Volatility Comparison

AXT, Inc. (AXTI) has a higher volatility of 49.61% compared to Arrowhead Pharmaceuticals, Inc. (ARWR) at 16.63%. This indicates that AXTI's price experiences larger fluctuations and is considered to be riskier than ARWR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	AXTI	ARWR	Difference
Volatility (1M) Calculated over the trailing 1-month period	49.61%	16.63%	+32.98%
Volatility (6M) Calculated over the trailing 6-month period	100.03%	46.06%	+53.97%
Volatility (1Y) Calculated over the trailing 1-year period	122.61%	71.17%	+51.44%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	91.12%	64.68%	+26.44%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	79.43%	74.13%	+5.30%

Financials

AXTI vs. ARWR - Profitability Comparison

The chart below illustrates the profitability comparison between AXT, Inc. and Arrowhead Pharmaceuticals, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

AXTI - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, AXT, Inc. reported a gross profit of 4.83M and revenue of 23.04M. Therefore, the gross margin over that period was 21.0%.

ARWR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Arrowhead Pharmaceuticals, Inc. reported a gross profit of 264.03M and revenue of 264.03M. Therefore, the gross margin over that period was 100.0%.

AXTI - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, AXT, Inc. reported an operating income of -3.83M and revenue of 23.04M, resulting in an operating margin of -16.6%.

ARWR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Arrowhead Pharmaceuticals, Inc. reported an operating income of 40.81M and revenue of 264.03M, resulting in an operating margin of 15.5%.

AXTI - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, AXT, Inc. reported a net income of -3.55M and revenue of 23.04M, resulting in a net margin of -15.4%.

ARWR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Arrowhead Pharmaceuticals, Inc. reported a net income of 30.81M and revenue of 264.03M, resulting in a net margin of 11.7%.